The Cancer Test That Wall Street Is Betting On
The Rise of Liquid Biopsy Technology Natera, a California-based diagnostics firm, has emerged as the frontrunner in the clinical adoption of molecular residual disease (MRD) testing, a revolutionary blood-based approach designed to detect cancer recurrence in survivors. As of late 2023 and early 2024, the company has captured a dominant share of the oncology market,…